SCHEMBL427627

SCHEMBL427627

Cc1cc(-c2ccccc2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 1.00
RAB9A P51151 2/20 0.66
NPC1 O15118 2/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
ALK Q9UM73 1/20 0.65
POLB P06746 1/20 0.61
GAA P10253 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HSD17B10 Q99714 1/20 0.56
TP53 P04637 1/20 0.53
LMNA P02545 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP19A1 P11511 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
PDE10A Q9Y233 1/20 0.52
AURKB Q96GD4 2/20 0.51
GSK3B P49841 2/20 0.51
AURKA O14965 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14097585 0.96 L3MBTL1 (0.92) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL19625266 0.85 L3MBTL1 (0.73) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL18803859 0.84 L3MBTL1 (0.72) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL2766145 0.83 RAB9A (0.71) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
Quinoline SCHEMBL28218102 0.82 L3MBTL1 (0.68) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL19632653 0.82 L3MBTL1 (0.69) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL3860074 0.81 L3MBTL1 (0.68) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL2360295 0.79 NPC1 (0.67) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL17183457 0.79 L3MBTL1 (0.66) L3MBTL1RAB9ANPC1SMN1; SMN2ALK
SCHEMBL15908507 0.79 NPC1 (0.67) L3MBTL1RAB9ANPC1SMN1; SMN2ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023004280-A1 SELECTIVE PYRAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-01-26 WO claimed
CN-102993096-A N-pyrazole amide derivative and preparation method thereof UNIV NINGBO 2013-03-27 CN claimed
US-20250331521-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING AN OXIME GROUP, AGRICULTURAL OR HORTICULTURAL HERBICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE COMPOUND OR THE HERBICIDE NIHON NOHYAKU CO., LTD. (JP) 2025-10-30 US disclosed
WO-2025094987-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING SULFONYL GROUP, AGRICULTURAL/HORTICULTURAL HERBICIDE CONTAINING SAME, AND USE THEREOF 日本農薬株式会社 2025-05-08 WO disclosed
EP-4480950-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING OXIME GROUP, AGRICULTURAL/HORTICULTURAL HERBICIDE CONTAINING SAID COMPOUND, AND USE OF BOTH OF FOREGOING Nihon Nohyaku Co., Ltd. (JP) 2024-12-25 EP disclosed
CN-118891254-A Nitrogen-containing heterocyclic compound having oxime group, agrohorticultural herbicide containing the same, and method of using the same 日本农药株式会社 2024-11-01 CN disclosed
WO-2023210792-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING OXIME GROUP, AGRICULTURAL/HORTICULTURAL HERBICIDE CONTAINING SAID COMPOUND, AND USE OF BOTH OF FOREGOING 日本農薬株式会社 2023-11-02 WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
WO-2003057673-A1 1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-17 WO disclosed
US-20030130281-A1 DPP IV inhibitors HOFFMAN-LA ROCHE INC. 2003-07-10 US disclosed
WO-2003037327-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA-ROCHE AG (CH) 2003-05-08 WO disclosed
WO-2003011868-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2003-02-13 WO disclosed
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-02-13 US disclosed
CN-1390864-A Additional polymerization catalyst and its production process SUMITOMO CHEMICAL CO (JP) 2003-01-15 CN disclosed
WO-2002100403-A1 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) ELI LILLY AND COMPANY (US) 2002-12-19 WO disclosed
EP-1266911-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-12-18 EP disclosed
WO-1997017379-A1 POLYMERIZATION CATALYSTS BOREALIS A/S (DK) 1997-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135152-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIP5K1C L3MBTL1 2305/4885RAB9A 794/4885NPC1 1153/4885
US-20250331521-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING AN OXIME GROUP, AGRICULTURAL OR HORTICULTURAL HERBICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE COMPOUND OR THE HERBICIDE DDT, HDHD5, HAAO L3MBTL1 2020/4885RAB9A 3423/4885NPC1 4568/4885
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer BRAP, MCM4, BOLA2; BOLA2B L3MBTL1 3636/4885RAB9A 3554/4885NPC1 3681/4885
US-20030130281-A1 DPP IV inhibitors DPP4, DPP3, DPP7 L3MBTL1 813/4885RAB9A 3016/4885NPC1 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.